Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer
Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology 2022, 167: 417-422. PMID: 37191644, DOI: 10.1016/j.ygyno.2022.10.014.Peer-Reviewed Original ResearchMeSH KeywordsCytoreduction Surgical ProceduresFemaleHumansNeoadjuvant TherapyOvarian NeoplasmsRetrospective StudiesConceptsKaplan-Meier survival analysisOutcomes of cytoreductionRetrospective cohort studyDays of chemotherapyCA 125 valuesMeier survival analysisLocal ethics boardCytoreductive outcomeMedian pfsCohort studyInhibitor useTreatment delayFunctional statusBRCA statusInclusion criteriaHigh riskPlatinum sensitivityStage IIIPatientsSurvival analysisEthics BoardHigh gradeSignificant differencesNACTPoly adenosine